IDH1 and glioblastoma: For patients with glioblastoma, there were no significant survival differences between IDH-mutant and IDH-wildtype tumors (IDH-mutant 1-year OS, 78% [61–100%] vs. IDH-wildtype 1-year OS, 57% [48–69%]; p = 0.200) (Figure 10).